Add like
Add dislike
Add to saved papers

Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.

BACKGROUND: To evaluate the effects of celecoxib, in combination with oxaliplatin, on tumour growth, cell apoptosis and angiogenesis in nude mice models.

MATERIALS AND METHODS: Xenograft mice model of colon cancer was established using the BALB/c nude mice. Medicine was administered respectively in different groups. Tumour volumes, the expression level of survivin, beta-catenin, VEGF mRNA level, the microvessel density and cell apoptosis were measured.

RESULTS: Celecoxib, oxaliplatin and combination use caused a tumour inhibition of 35%, 31% and 63% respectively. Compared with control group, a significant redation of angiogenesis and the levels of COX-2, survivin and beta-cantenin protein, and increase of cell apoptosis were detected in tumors in celecoxib group. Celecoxib in combination with oxaliplatin could further promote cell apoptosis and reduce beta-catenin protein expression.

CONCLUSION: Celecoxib could inhibit tumor growth and enhance the antitumor effects of oxaliplatin through their synergistic role in inhibiting different targets.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app